Evaluation of serum immunoglobulin (IgG, IgM, IgA) in potentially malignant disorders of oral cavity - A case control study.
IgA
IgG
IgM
Potentially malignant disorder
Serum immunoglobulin
Tumour marker
Journal
Journal of oral biology and craniofacial research
ISSN: 2212-4268
Titre abrégé: J Oral Biol Craniofac Res
Pays: Netherlands
ID NLM: 101619156
Informations de publication
Date de publication:
Historique:
received:
16
08
2020
revised:
01
09
2020
accepted:
04
09
2020
entrez:
2
10
2020
pubmed:
3
10
2020
medline:
3
10
2020
Statut:
ppublish
Résumé
Only few studies have been done to evaluate level of serum immunoglobulins (IgG,IgM,IgA) in patients with Potentially Malignant Disorders (PMD) like Leukoplakia, Oral Submucous Fibrosis (OSMF) and Oral Lichen Planus (OLP) as tumour markers. To estimate the serum immunoglobulins level (IgG, IgM, IgA) in leukoplakia, OSMF and oral lichen planus (OLP) patients and its comparison with levels among control groups and Weather these values can be used to predict severity of disease or not. 30 patients with different potentially malignant disorders like leukoplakia, OSMF and oral lichen planus and 30 healthy controls were selected at random and subjected for analysis of serum IgG, IgA, IgM. Statistical methods employed were mean, standard deviation and ANOVA test. We observed significant elevated levels of all the immunoglobulins in leukoplakia, OSMF and oral lichen planus when compared with the control group and levels were increasing with clinical stages of OSMF All these immunoglobulins are indicative of tumour burden or transformation of malignancy in higher stage and might be employed as prognostic indicators in these disorders.
Sections du résumé
BACKGROUND
BACKGROUND
Only few studies have been done to evaluate level of serum immunoglobulins (IgG,IgM,IgA) in patients with Potentially Malignant Disorders (PMD) like Leukoplakia, Oral Submucous Fibrosis (OSMF) and Oral Lichen Planus (OLP) as tumour markers.
AIMS AND OBJECTIVES
OBJECTIVE
To estimate the serum immunoglobulins level (IgG, IgM, IgA) in leukoplakia, OSMF and oral lichen planus (OLP) patients and its comparison with levels among control groups and Weather these values can be used to predict severity of disease or not.
MATERIALS AND METHODS
METHODS
30 patients with different potentially malignant disorders like leukoplakia, OSMF and oral lichen planus and 30 healthy controls were selected at random and subjected for analysis of serum IgG, IgA, IgM. Statistical methods employed were mean, standard deviation and ANOVA test.
RESULTS
RESULTS
We observed significant elevated levels of all the immunoglobulins in leukoplakia, OSMF and oral lichen planus when compared with the control group and levels were increasing with clinical stages of OSMF
CONCLUSIONS
CONCLUSIONS
All these immunoglobulins are indicative of tumour burden or transformation of malignancy in higher stage and might be employed as prognostic indicators in these disorders.
Identifiants
pubmed: 33005564
doi: 10.1016/j.jobcr.2020.09.002
pii: S2212-4268(20)30138-X
pmc: PMC7511741
doi:
Types de publication
Journal Article
Langues
eng
Pagination
665-669Informations de copyright
© 2020 Craniofacial Research Foundation. Published by Elsevier B.V. All rights reserved.
Références
J Indian Soc Pedod Prev Dent. 2020 Apr-Jun;38(2):190-199
pubmed: 32611867
J Indian Dent Assoc. 1991 Mar;62(3):51-3, 59
pubmed: 1820393
J Oral Maxillofac Pathol. 2018 Jan-Apr;22(1):18-26
pubmed: 29731552
Br J Radiol. 1988 Apr;61(724):305-8
pubmed: 3259446
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 Jun;125(6):582-590
pubmed: 29673799
Int Arch Allergy Immunol. 1994 May;104(1):97-100
pubmed: 7950411
Indian J Dent Res. 2010 Jan-Mar;21(1):10-5
pubmed: 20427899
Indian J Med Res. 2010 Aug;132:129-49
pubmed: 20716813
Indian J Cancer. 1987 Mar;24(1):9-14
pubmed: 3428924
J Oral Biol Craniofac Res. 2019 Oct-Dec;9(4):311-314
pubmed: 31334003
J Otolaryngol Head Neck Surg. 2020 Jan 8;49(1):3
pubmed: 31915073
Subst Use Misuse. 2020;55(9):1413-1421
pubmed: 32569538
Arch Oral Biol. 1969 Apr;14(4):351-64
pubmed: 4182947
Eur J Surg Oncol. 1992 Feb;18(1):31-6
pubmed: 1737590
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):552-568
pubmed: 32939334
Cancer. 1986 Dec 15;58(12):2628-31
pubmed: 3779612
J Oral Sci. 2011 Mar;53(1):97-102
pubmed: 21467820
J Oral Biol Craniofac Res. 2020 Oct-Dec;10(4):356-360
pubmed: 32714788
Indian J Dent Res. 1994 Jul-Sep;5(3):81-7
pubmed: 9495103
Indian J Pathol Microbiol. 1995 Jan;38(1):1-3
pubmed: 8919462